$599

Novo Initiates Ph1 Study for New Obesity Asset; Lemonaid GLP-1RA and Compounded Semaglutide Program; New Semaglutide HF Analysis Published; Alnylam’s Ph3 ATTR-CM Vutrisiran Data

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Lemonaid Health, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Register
Already a member? Log in here